Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Coherent Biopharma (Suzhou)

Request full access

Bi-specific ligand-drug conjugates for targeted oncology therapeutics

ChinaFounded 2016Biotech & Life Sciences

About Coherent Biopharma (Suzhou)

Coherent Biopharma (Suzhou) Co. Ltd. is a clinical-stage biopharmaceutical company founded in 2016 by Dr. Baohua (Robert) Huang. The company focuses on the research, development, and commercialization of bi-targeting ligand-drug conjugate (Bi-XDC) drugs for oncology and other chronic diseases. Dr. Huang, who serves as Chairman and CEO, is a serial entrepreneur with over 30 years of experience in the pharmaceutical and biotech industries, having held roles at major companies like Abbott Labs and Amgen (Tularik). He holds a PhD in Biochemistry from The Ohio State University, an MBA from Cornell University, and has authored numerous scientific papers and patents.

Coherent Biopharma's core technology is its proprietary Bi-XDC platform, which is designed to empower molecules that were previously considered undruggable. This technology is distinct from antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), aiming to offer a better therapeutic window, improved plasma stability, and more targeted drug enrichment in tumors. The platform includes several components like the BEST™ Platform and the C-PROTAC Platform, which enable the specific delivery of bioactive molecules to diseased tissues. The business model centers on advancing its pipeline of drug candidates through clinical trials to address unmet medical needs in cancer treatment. The company operates globally with a management organization across China, the U.S., and Australia.

The company's pipeline includes several candidates in various stages of clinical development. Its lead asset, CBP-1008, is a bispecific conjugate targeting FRα and TRPV6 for cancers such as platinum-resistant ovarian cancer and triple-negative breast cancer. CBP-1018 targets PSMA and is being studied for metastatic castration-resistant prostate cancer (mCRPC). Another key candidate, CBP-1019, is a next-generation conjugate for solid malignancies like endometrial, colorectal, and pancreatic cancer. The company has received Fast Track Designation from the U.S. FDA for both CBP-1008 and CBP-1019, expediting their development and review process. Coherent Biopharma has secured significant funding to advance its clinical trials, including raising $100 million in Series B and B+ financing rounds in 2023.

Source: Dealroom company data

At a glance

Status
Operational
Employees
10
Open positions
None listed
Dealroom signal
24.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing May 2023 $100M $400M Shanghai Lianhe Investment · Suzhou Industrial Park Science and Technology Innovation Fund · Hefei Hi-Tech Venture Capital · Hefei Industry Investment Group ↗
SERIES BOther financing Jul 2022 $0 — HM Capital · YunFeng Capital · ABC International Holdings ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Coherent Biopharma (Suzhou) website traffic

Latest recorded traffic for Coherent Biopharma (Suzhou) is 410 monthly website visits, down 82.9% over the last three months. Coherent Biopharma (Suzhou)'s team grew 0% over the past year.

Latest monthly visits410 3-month web change-82.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Coherent Biopharma (Suzhou) in its local ecosystem

Live from Dealroom

The Coherent Biopharma (Suzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

  • Frontline BioVentures
  • 6 Dimensions Capital
  • HM Capital
  • YunFeng Capital
  • ABC International Holdings
  • Shanghai Lianhe Investment
  • Suzhou Industrial Park Science and Technology Innovation Fund
  • Hefei Hi-Tech Venture Capital
  • Hefei Industry Investment Group
  • Leading Venture Capital
  • Shengdi Investment
Employees 10 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Coherent Biopharma (Suzhou) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Coherent Biopharma (Suzhou)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.